Doctor of Podiatric Medicine Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kyle Smith

Podiatrist, Foot & Ankle Surgery Toledo, OH Doctor of Podiatric Medicine

NPI 1821653155 CMS profile 11309336

4235 Secor Rd, Bldg 3, Flr 1, Toledo, OH 43623

Open in the dashboard

General payments

$72,484

295 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Smith of Toledo, OH is reported in the CMS Open Payments database as having received $72,484 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,481 74
2024 General $36,677 104
2023 General $5,546 57
2022 General $9,424 54
2021 General $1,356 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Smith
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Kyle Smith were reported at $19,481. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Kyle Smith Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $0 $191 $62–$691 $114
2021 $1,356 $329 $104–$1,341 $132
2022 $9,424 $419 $125–$1,611 $149
2023 $5,546 $377 $128–$1,164 $160
2024 $36,677 $394 $134–$1,168 $164
2025 $19,481 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Integra LifeSciences Corporation $30,651 91 payments
  2. Orthofix Medical, Inc. $23,622 63 payments
  3. Stryker Corporation $6,264 51 payments
  4. Rock Medical Orthopedics, Inc. $3,736 10 payments
  5. Access Pro Medical, LLC $1,983 7 payments
  6. Vilex in Tennessee, Inc. $1,983 5 payments
  7. Arthrex, Inc. $1,929 7 payments
  8. Tulavi Therapeutics, Inc. $581 4 payments
  9. Smith+Nephew, Inc. $485 22 payments
  10. Arteriocyte Medical Systems, Inc. $313 2 payments
  11. Other $936 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $30,270 88 payments
  2. Consulting Fee $25,166 9 payments
  3. Food and Beverage $10,525 190 payments
  4. Education $6,068 5 payments
  5. Long term medical supply or device loan $432 2 payments
  6. Entertainment $23 1 payment
Products named General payments · program years 2021–2025
  1. Integra Recon-Skin And Wound $27,861 68 payments
  2. Integra Recon-Skin And Wound $27,684 67 payments
  3. TrueLok $23,746 61 payments
  4. PRIMATRIX $7,499 51 payments
  5. INTEGRA DERMAL REGENERATION TEMPLATE $6,978 47 payments
  6. Integra Recon-Skin And Wound $6,913 46 payments
  7. Matriderm $1,983 7 payments
  8. REDEMPTION $1,983 5 payments
  9. GENTRIX $1,785 11 payments
  10. VARIAX $1,469 18 payments
  11. Other $12,903 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

252

Median for Podiatry: 160

Drug cost

$2,303

Median for Podiatry: $2,368

Branded share of claims

16.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort Brand 15 $766
Doxycycline Hyclate Generic 44 $380
Gabapentin Generic 14 $254
Ciprofloxacin Hcl Generic 22 $200
Ammonium Lactate Generic 17 $199
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $111
Methylprednisolone Generic 20 $100
Meloxicam Generic 47 $98
Levofloxacin Generic 12 $58
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $52

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$87,314

Of which drugs: $183

Medicare patients

165

Average age 72

Services billed

2,035

78 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Diabetes 42%
Ischemic heart disease 33%
Chronic kidney disease 32%
Depression 31%
Heart failure 22%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 1,281 $133
Injection, methylprednisolone acetate, 40 mg J1030 Office 15 16 $50

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $33
$33 — —
Qutenza
  • Averitas Pharma Inc. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record